Shots:

• Tonix & Boston Children's Hospital collaborated to study TNX-1500 (Fc-modified anti-CD40L mAb) in GvHD after HCT in animals
• The primary objective of the preclinical research is to study the activity of TNX-1500 administered prophylactically to modify GvHD progression after HCT & support an IND application for human studies. The P-I study of TNX-1500 is expected to be initiated in H1’23
• In animal studies, TNX-1500 showed activity in preventing organ rejection & was well tolerated in non-human primates. Non-human primate models of cardiac & kidney allograft transplantation successfully and safely prevented pathologic alloimmunity by blocking CD40L with TNX-1500 monotx. without clinical thrombosis

Ref: Tonix | Image: Tonix